<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1410158</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Identification of novel biomarkers related to neutrophilic inflammation in COPD</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Huang</surname>
<given-names>Yuchen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2699643"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Niu</surname>
<given-names>Yang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2703778"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xuezhao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2364508"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Xiaochen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1990893"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Yuanzhou</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Liu</surname>
<given-names>Xiansheng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1260829"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>, <addr-line>Wuhan</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Key Laboratory of Pulmonary Diseases of National Health Commission, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology</institution>, <addr-line>Wuhan</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Theodoros Karampitsakos, University of South Florida, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Ourania Papaioannou, General University Hospital of Patras, Greece</p>
<p>Baicun Li, China-Japan Friendship Hospital, China</p>
<p>John Benjamin, Vanderbilt University Medical Center, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Xiansheng Liu, <email xlink:href="mailto:doctorliu69@126.com">doctorliu69@126.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1410158</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>03</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>05</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Huang, Niu, Wang, Li, He and Liu</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Huang, Niu, Wang, Li, He and Liu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Chronic obstructive pulmonary disease (COPD) is one of the most prevalent chronic respiratory diseases and the fourth cause of mortality globally. Neutrophilic inflammation has a vital role in the occurrence and progression of COPD. This study aimed to identify the novel hub genes involved in neutrophilic inflammation in COPD through bioinformatic prediction and experimental validation.</p>
</sec>
<sec>
<title>Methods</title>
<p>Both the single-cell RNA sequencing (scRNA-seq) dataset (GSE173896) and the RNA sequencing (RNA-seq) dataset (GSE57148) were downloaded from the Gene Expression Omnibus (GEO) database. The Seurat package was used for quality control, dimensions reduction, and cell identification of scRNA-seq. The irGSEA package was used for scoring individual cells. The Monocle2 package was used for the trajectory analysis of neutrophils. The CIBERSORT algorithm was used for analysis of immune cell infiltration in the lungs of COPD patients and controls in RNA-seq dataset, and weighted gene co-expression network analysis (WGCNA) correlated gene modules with neutrophil infiltration. The Mendelian randomization (MR) analysis explored the causal relationship between feature DEGs and COPD. The protein&#x2013;protein interaction (PPI) network of novel hub genes was constructed, and real-time quantitative polymerase chain reaction (qRT-PCR) was used to validate novel hub genes in clinical specimens.</p>
</sec>
<sec>
<title>Results</title>
<p>In scRNA-seq, the gene sets upregulated in COPD samples were related to the neutrophilic inflammatory response and TNF-&#x3b1; activation of the NF-&#x3ba;B signaling pathway. In RNA-seq, immune infiltration analysis showed neutrophils were upregulated in COPD lung tissue. We combined data from differential and modular genes and identified 51 differential genes associated with neutrophilic inflammation. Using MR analysis, 6 genes were explored to be causally associated with COPD. Meanwhile, 11 hub genes were identified by PPI network analysis, and all of them were upregulated. qRT-PCR experiments validated 9 out of 11 genes in peripheral blood leukocytes of COPD patients. Furthermore, 5 genes negatively correlated with lung function in COPD patients. Finally, a network of transcription factors for NAMPT and PTGS2 was constructed.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This study identified nine novel hub genes related to the neutrophilic inflammation in COPD, and two genes were risk factors of COPD, which may serve as potential biomarkers for the clinical severity of COPD.</p>
</sec>
</abstract>
<kwd-group>
<kwd>bioinformatics</kwd>
<kwd>biomarker</kwd>
<kwd>chronic obstructive pulmonary disease</kwd>
<kwd>Mendelian randomization</kwd>
<kwd>neutrophilic inflammation</kwd>
<kwd>single-cell RNA sequencing</kwd>
</kwd-group>
<counts>
<fig-count count="11"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="61"/>
<page-count count="16"/>
<word-count count="6008"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Inflammation</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Chronic obstructive pulmonary disease (COPD) is the most common chronic respiratory disease characterized by persistent respiratory symptoms and airflow limitation accompanied by neutrophil infiltration in the airways and overproduction of mucus (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). COPD is the fourth cause of mortality globally, imposing a heavy economic and social burden on the world (<xref ref-type="bibr" rid="B3">3</xref>). In China, a cross-sectional survey showed that the general prevalence of COPD, as defined by spirometry, was 8.6% in people aged 20 years and over and 13.7% in people aged 40 years and over. In 2019, about 212.3 million cases of COPD were recorded worldwide, with an age-standardized prevalence rate of 2,638.2 cases per 100,000 people. COPD led to 3.3 million deaths, with an age-standardized mortality rate of 42.5 per 100,000 population (<xref ref-type="bibr" rid="B4">4</xref>).</p>
<p>In COPD patients, neutrophil populations are increased by chemotactic mediators released from airway epithelial cells and macrophages in the lungs (<xref ref-type="bibr" rid="B5">5</xref>). However, the cellular and molecular variations within the systemic immune system of patients in COPD, particularly neutrophils, the most abundant immune cells in the circulation are poorly understood. Neutrophils are significant contributors to the development of COPD due to their production of cytokines, inflammatory mediators, oxygen-free radicals, and elastase (<xref ref-type="bibr" rid="B6">6</xref>). These substances cause inflammation in the airways, lung parenchyma, and pulmonary vasculature, destroying lung tissue (<xref ref-type="bibr" rid="B7">7</xref>). Furthermore, the number of neutrophils in COPD patients negatively correlates with lung function (<xref ref-type="bibr" rid="B8">8</xref>). Although neutrophils play a crucial role in COPD, the molecular mechanisms require further elucidation.</p>
<p>Recent applications of single-cell RNA sequencing (scRNA-seq) technologies have uncovered previously unknown molecular and functional diverse aspects of neutrophils, both in homeostasis and inflammatory disease (<xref ref-type="bibr" rid="B9">9</xref>). Notably, scRNA-seq studies on COPD have shown a significant underrepresentation of neutrophils. Therefore, we hypothesized that this innovative technique would allow us to delineate molecular and phenotypic variations in this crucial cell type in COPD and identify hub genes involved in neutrophil inflammation. These markers can act as proxies for disease progression to develop new treatment interventions.</p>
<p>Mendelian randomization (MR) is an epidemiological analysis method that utilizes genetic variation to identify causal associations between exposure factors and outcomes (<xref ref-type="bibr" rid="B10">10</xref>). Compared to traditional observational studies, MR is less susceptible to confounding and reverse causation. In this study, we further illustrated the causal role of hub genes in the risk of developing COPD by a two-sample MR approach.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Data source</title>
<p>The scRNA dataset (GSE173896) and the RNA-sequencing (RNA-seq) dataset (GSE57148) were obtained from GEO (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo">http://www.ncbi.nlm.nih.gov/geo</ext-link>). The samples in both datasets were lung tissues from COPD and control subjects.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Analysis of single-cell sequencing data</title>
<p>Four COPD (GSM5282538, GSM5282539, GSM5282540, and GSM5282541) and three control nonsmokers (GSM5282546, GSM5282547, and GSM5282548) scRNA-seq lung tissue samples were obtained from GSE173896. The total number of cells in the COPD and control groups was approximately the same. Afterward, the Seurat package initially filtered scRNA-seq data to obtain higher-quality cells (<xref ref-type="bibr" rid="B11">11</xref>). For further analysis, cells and genes must fulfill the three quality control criteria: 1. The detected gene in at least three cells. 2. Detected at least 200 genes per cell. 3. No more than 15% of the genes are mitochondrial genes. With quality control, the overall count of cells in the COPD and control groups was 11,024 and 11,225, respectively. The canonical correlation analysis (CCA) algorithm integrated the seven samples and removed batch effects. Then, 3,000 highly variable genes were chosen for analysis, and the number of principal components (PCs) was programmed to 50 to get clusters of cells, which were visualized as a &#x201c;UMAP&#x201d; plot (<xref ref-type="bibr" rid="B12">12</xref>). All cells were subsequently labeled by the marker genes for each cell type. FindMarker was used to identify differential genes.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Trajectory analysis and gene set enrichment analysis</title>
<p>The Monocle2 was applied to perform single-cell trajectory analysis (<xref ref-type="bibr" rid="B13">13</xref>). All neutrophil objects were extracted, and the DDRTree method was used to reduce the dimension of cells. Then, the reduce Dimension function was implemented to determine the type of cell differentiation state. Finally, the &#x201c;plot cell trajectory&#x201d; function was employed to visualize the differentiation trajectory of cells.</p>
<p>Bioinformatics (<ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.com.cn/">https://www.bioinformatics.com.cn/</ext-link>) website was an open online platform for data processing and visualization. Gene Set Enrichment Analysis (GSEA) was used to identify enriched GO terms and KEGG associated with cell differentiation state. Sorting all of the differential genes according to logFC and GSEA was conducted on the website.</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Identification of significantly related pathways in all cells</title>
<p>The level of gene set enrichment in each cell was assessed using the irGSEA package. This package was used to score individual cells and to generate numerous gene set enrichment score matrices. The half vlnplot and density scatterplot visualized some specific enriched pathways.</p>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>Immune infiltration analysis</title>
<p>We calculated the extent of immune cell infiltration in COPD and control lung tissue samples in GSE57148 by using the CIBERSORT algorithm. This algorithm set the PERM to 1000 and set the cutoff to p &lt; 0.05 (<xref ref-type="bibr" rid="B14">14</xref>). The Pheatmap package created a heat map of different immune cells, and the Vioplot package displayed the abundance. A correlation heat map was created to visualize the correlation among infiltrating immune cells. Furthermore, the correlation of critical genes with the differential immunity cells was analyzed.</p>
</sec>
<sec id="s2_6">
<label>2.6</label>
<title>WGCNA in GSE57148</title>
<p>Weighted gene co-expression network analysis (WGCNA) was performed to construct modules with similar expression pattern genes on GSE57148 (<xref ref-type="bibr" rid="B15">15</xref>). Firstly, outlier samples and low-expressed genes were eliminated. Secondly, the adjacency matrix was built based on an optimal soft threshold and converted into a topological overlap matrix. Then, a hierarchical clustering tree was constructed to classify the highly co-expressed genes into the same module. Finally, COPD and neutrophils were identified as characteristics to compute the correlation between gene modules and traits.</p>
</sec>
<sec id="s2_7">
<label>2.7</label>
<title>DEGs detection in GSE57148</title>
<p>COPD samples (n = 96) and normal samples (n = 90) in the GSE57148 dataset were analyzed using the limma package to screen for differentially expressed genes (DEGs), with an adjusted p-value of &lt; 0.05 and | log2(fold change, FC) | &gt; 0.4 as thresholds.</p>
</sec>
<sec id="s2_8">
<label>2.8</label>
<title>Functional enrichment</title>
<p>GO analysis was a popular approach for massive functional enrichment, encompassing biological process (BP), cellular component (CC), and molecular function (MF). KEGG was a globally accessible database storing essential data on genomes, biological pathways, diseases, and drugs. GO terms and KEGG pathway analysis were annotated for gene function by the clusterProfiler package, and the top-ranked results were visualized (<xref ref-type="bibr" rid="B16">16</xref>).</p>
</sec>
<sec id="s2_9">
<label>2.9</label>
<title>Mendelian randomization analysis between genes and COPD</title>
<p>The MR analysis was to investigate the causality between DEGs and the risk of COPD, where the instrumental variables (IVs) were single nucleotide polymorphisms (SNPs). The cis-eQTL data of DEGs were obtained from eQTLGen, and GWAS statistics for COPD outcome were obtained from integrated epidemiology unit (IEU) database (ukb-b-20464) (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>). The cis-eQTL data were used as exposure factors and SNPs with P-value &lt; 5 &#xd7; 10<sup>&#x2013;8</sup> were used for the MR analysis. If no suitable SNPs were available at the stringent threshold, the threshold was loosened to 5 &#xd7; 10<sup>&#x2013;6</sup>. There were still no relevant SNPs, so this cis-eQTL data was not used for MR analysis. All SNPs were identified 100 kb upstream and downstream of the corresponding gene location, with a threshold for Linkage disequilibrium (LD) of R2 &lt; 0.2 and a physical distance threshold of 250 kb.</p>
<p>The TwoSampleMR package performed MR analysis. MR estimates were calculated for each SNP using the Wald ratio method. If more than one SNP was available, MR estimates were weighted by the inverse variance of the ratio estimates (inverse variance weighted, IVW). Cochran&#x2019;s Q statistic was used to test for heterogeneity (<xref ref-type="bibr" rid="B19">19</xref>). When the number of SNPs was no less than three, MR-Egger regression evaluated potential horizontal pleiotropy (<xref ref-type="bibr" rid="B20">20</xref>).</p>
</sec>
<sec id="s2_10">
<label>2.10</label>
<title>PPI analysis</title>
<p>The protein-protein interaction (PPI) network was built on the STRING online site (<xref ref-type="bibr" rid="B21">21</xref>). An interaction score greater than 0.4 (medium confidence score) was considered meaningful. Then, the PPI network was further analyzed in Cytoscape. CytoHubba, a Cytoscape plugin that discovered hub terms and sub-networks from interaction groups, was used to analyze PPI network hub genes. The top 10 genes were confirmed using the maximal clique centrality (MCC) computing method with the Cytohubba plugin.</p>
</sec>
<sec id="s2_11">
<label>2.11</label>
<title>Quantitative real-time polymerase chain reaction in leukocytes</title>
<p>Peripheral blood samples in this study were obtained from Tongji Hospital, Wuhan, China. All subjects signed an informed consent form. The Ethics Committee of Tongji Hospital, Huazhong University of Science and Technology had approved this research.</p>
<p>Peripheral blood was centrifuged to obtain blood cells, which were treated with erythrocyte lysis buffer (TBD, China) to obtain leukocytes for the assay. The total RNA of leukocytes was extracted with RNAiso plus kit (Takara, Japan), followed by reverse transcription to cDNA using cDNA RT-PCR kit (Takara, Japan). qRT-PCR was performed using a CFX Connect Real-Time System (Bio-Rad, USA) with SYBR Premix Ex Taq (Takara, Japan) and the specific primers. The primers (Sangon Biotech, China) were shown in <xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>:</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Primer sequences for validating genes.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" rowspan="2" align="center">Gene name</th>
<th valign="middle" colspan="2" align="center">Primer sequence (5&#x2019;-3&#x2019;)</th>
</tr>
<tr>
<th valign="middle" align="center">Forward</th>
<th valign="middle" align="center">Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">ACTB</td>
<td valign="middle" align="center">AGAAAATCTGGCACCACACCT</td>
<td valign="middle" align="center">AGAAAATCTGGCACCACACCT</td>
</tr>
<tr>
<td valign="middle" align="center">IL1B</td>
<td valign="middle" align="center">GCCCTAAACAGATGAAGTGCTC</td>
<td valign="middle" align="center">GAGATTCGTAGCTGGATGCC</td>
</tr>
<tr>
<td valign="middle" align="center">MCL1</td>
<td valign="middle" align="center">TAACAAACTGGGGCAGGATT</td>
<td valign="middle" align="center">TCCCGTTTTGTCCTTACGAG</td>
</tr>
<tr>
<td valign="middle" align="center">PTGS2</td>
<td valign="middle" align="center">CTGGCGCTCAGCCATACAG</td>
<td valign="middle" align="center">CGCACTTATACTGGTCAAATCCC</td>
</tr>
<tr>
<td valign="middle" align="center">CXCL2</td>
<td valign="middle" align="center">GGCAGAAAGCTTGTCTCAACCC</td>
<td valign="middle" align="center">CTCCTTCAGGAACAGCCACCAA</td>
</tr>
<tr>
<td valign="middle" align="center">NAMPT</td>
<td valign="middle" align="center">ATCCTGTTCCAGGCTATTCTGT</td>
<td valign="middle" align="center">CCCCATATTTTCTCACACGCAT</td>
</tr>
<tr>
<td valign="middle" align="center">CDKN1A</td>
<td valign="middle" align="center">CCCCATATTTTCTCACACGCAT</td>
<td valign="middle" align="center">GGTTCTGACGGACATCCCCA</td>
</tr>
<tr>
<td valign="middle" align="center">EGR1</td>
<td valign="middle" align="center">AGCAGCACCTTCAACCCTCAGG</td>
<td valign="middle" align="center">GAGTGGTTTGGCTGGGGTAACT</td>
</tr>
<tr>
<td valign="middle" align="center">SOD2</td>
<td valign="middle" align="center">CTGGACAAACCTCAGCCCTAAC</td>
<td valign="middle" align="center">AACCTGAGCCTTGGACACCAAC</td>
</tr>
<tr>
<td valign="middle" align="center">CXCL3</td>
<td valign="middle" align="center">TTCACCTCAAGAACATCCAAAGTG</td>
<td valign="middle" align="center">TTCTTCCCATTCTTGAGTGTGGC</td>
</tr>
<tr>
<td valign="middle" align="center">TNFAIP3</td>
<td valign="middle" align="center">CTCAACTGGTGTCGAGAAGTCC</td>
<td valign="middle" align="center">TTCCTTGAGCGTGCTGAACAGC</td>
</tr>
<tr>
<td valign="middle" align="center">ZFP36</td>
<td valign="middle" align="center">GACTGAGCTATGTCGGACCTT</td>
<td valign="middle" align="center">GAGTTCCGTCTTGTATTTGGGG</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2_12">
<label>2.12</label>
<title>Regulatory network construction</title>
<p>The NetworkAnalyst online tool was used to construct a gene regulation network of the hub gene&#x2013;transcription factor interaction network. The transcription factor data were obtained from the JASPAR database to build the network (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). Subsequently, the results were visualized using Cytoscape.</p>
</sec>
<sec id="s2_13">
<label>2.13</label>
<title>Statistical analysis</title>
<p>All data was analyzed by R (version 4.1.3) and GraphPad Prism 8 Software. For normally and non-normally distributed data, we used an unpaired t-test and a non-parametric test to compare differences between groups, respectively. Pearson correlation analysis was used to estimate the correlation. Unless explicitly stated, the p-value less than 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Quality control and dimension reduction in scRNA-seq GSE173896</title>
<p>The workflow of this study was presented in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>.&#xa0;A quality control procedure was performed on the scRNA-seq dataset. As shown in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>, specific low-quality cells were excluded based on their gene expression profile to avoid misinterpretation of the data. The mitochondrial proportion was used as a threshold to filter out low-quality cells. The CCA algorithm integrated the datasets from four COPD patients and three controls (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>). According to the expression level of marker genes (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>), all cells were classified as 16 clusters and annotated into 14 cell types based on the marker genes: T cells (marked with CD3D, CD2, and CD69), neutrophils (FCN1 and S100A9), dendritic cells (TGFBI and HLA-DMB), mast cells (KIT and TPSAB1), NK cells (CCL5, NKG7, GNLY, and CD247), B cells (CD79A, CD79B, and IGHG3), macrophages (MARCO, MSR1, and MRC1), alveolar type 1 cells (AGER, KRT7, and TSPAN13), alveolar type 2 cells (SFTPD, SFTA2, SLC34A2, and ABCA3), club epithelial cells (BIRC5, KRT19, and CXCL17), ciliated epithelial cells (CAPS, RSPH1, PIFO, and TSPAN1), endothelial cells (CALCRL and RAMP2), fibroblasts (COL1A2 and COL6A2), and smooth muscle cells (CALD1, TAGLN, and NOTCH3)(<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2D</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Flow chart of this study.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1410158-g001.tif"/>
</fig>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Quality control and dimension reduction in scRNA-seq GSE173896. <bold>(A)</bold> The proportion of mitochondrial genes was adjusted to ensure the quality of cell samples. The proportion of mitochondrial genes per cell was less than 15%. <bold>(B)</bold> UMAP dimensional plot after adjusting for batch effects. <bold>(C)</bold> Dot plot of z-scores for marker gene expression values. Dot size reflected the percentage of cells with gene expression; color corresponded to the magnitude of gene expression. <bold>(D)</bold> UMAP of 14 cell types in scRNA-seq GSE173896.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1410158-g002.tif"/>
</fig>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Single-cell rank-based gene set enrichment analysis</title>
<p>According to the hallmark gene sets collected from the MsigDB database, we used the irGSEA package to calculate each cell&#x2019;s gene set enrichment score. Overall, there were two hallmark gene sets upregulated in COPD samples: INFLAMMATORY-RESPONSE and TNFA-SIGNALING-VIA-NFKB. At the same time, the two gene sets were significantly downregulated for control samples (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). Next, the same operation was on different types of cells. The two gene sets were both upregulated in neutrophils and DCs (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>). INFLAMMATORY_RESPONSE gene set was significantly enriched in neutrophils (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref> and <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3D</bold>
</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Single-cell rank-based gene set enrichment analysis. <bold>(A)</bold> Heatmap plot of co-upregulated or co-downregulated gene sets per group in RRA. &#x201c;INFLAMMATORY-RESPONSE&#x201d; and &#x201c;TNFA-SIGNALING-VIA-NFKB&#x201d; were upregulated in the COPD group. <bold>(B)</bold> Heatmap plot of co-upregulated or co-downregulated gene sets per cell type in RRA. &#x201c;INFLAMMATORY-RESPONSE&#x201d; and &#x201c;TNFA-SIGNALING-VIA-NFKB&#x201d; were upregulated in neutrophils and DCs. <bold>(C)</bold> Half vlnplot of &#x201c;HALLMARK-INFLAMMATORY-RESPONSE&#x201d; in Ucell among clusters. <bold>(D)</bold> Density scatterplot of &#x201c;HALLMARK-INFLAMMATORY-RESPONSE&#x201d; in Ucell on UMAP plot. RRA, robust rank aggregation.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1410158-g003.tif"/>
</fig>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Enrichment analysis and pseudotime analysis of neutrophils in the single-cell dataset GSE173896</title>
<p>Neutrophilic inflammation predominates in the pathogenesis of COPD. The FindMarkers method was employed to identify genes differentially expressed in neutrophils from COPD patients and controls, revealing many inflammatory and immune responses-associated biological processes in COPD (<xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Figure&#xa0;1</bold>
</xref>). Thus, we performed a simulation analysis on the cell trajectory differentiation of all neutrophils. It was shown that the darker the blue color, the earlier the cells differentiated, indicating that the neutrophils differentiate from the left to the right with the differentiation of time, and the latest differentiated cell was represented by the lightest blue (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>). Neutrophils labeled with different colors had three differentiated states, with the red one on the left being the earliest differentiated type (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>). The differentiation process between COPD and control neutrophils was then investigated, and the results showed that COPD neutrophils differentiated later, whereas control neutrophils differentiated earlier (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4C</bold>
</xref>). All the cells analyzed were neutrophils (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4D</bold>
</xref>). The GSEA was conducted in neutrophils of different differentiation states to investigate the relationships between pseudotime and gene functions and showed that the latest differentiated neutrophils were mainly associated with the upregulation of inflammatory and immune responses (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4E&#x2013;G</bold>
</xref>, <xref ref-type="supplementary-material" rid="SF2">
<bold>Supplementary Figure&#xa0;2</bold>
</xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Pseudotime analysis and enrichment analysis of neutrophils in scRNA-seq GSE173896. <bold>(A)</bold> Timing differences in cell differentiation. Darker blue represented an earlier stage of differentiation, while lighter blue indicated a later stage of differentiation. This served as a starting point for subsequent analysis. <bold>(B)</bold> Three stages of neutrophil differentiation. State 1 was the earliest stage of differentiation, and state 2 was the latest. <bold>(C)</bold> Differences in differentiation between COPD neutrophils and normal neutrophils. The turquoise represented control, and the red represented COPD. <bold>(D)</bold> All cells analyzed were neutrophils. <bold>(E)</bold> GSEA of DEGs on KEGG in state.1. <bold>(F)</bold> GSEA of DEGs on KEGG in state.2. <bold>(G)</bold> GSEA of DEGs on KEGG in state.3.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1410158-g004.tif"/>
</fig>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Immune cells infiltrating analysis in GSE57148</title>
<p>The RNA sequencing dataset GSE57148 included 98 COPD and 91 normal samples. The cell type proportions in each sample were calculated by the CIBERSORT algorithm, and different colors represented different immune cells (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A</bold>
</xref>). There were differences in the proportions of four types of immune cells, including neutrophils, M2-type macrophages, resting NK cells, and T follicular helper cells, in COPD samples and normal samples. Furthermore, the proportion of neutrophils was significantly increased in COPD samples (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5B</bold>
</xref>). In <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5C</bold>
</xref>, the correlation heatmap indicated that neutrophils correlated negatively with Dendritic cells resting (p&lt;0.01, r= -0.217), CD8 T cells (p&lt;0.01, r= -0.216), T follicular helper cells (p&lt;0.01, r= -0.305), NK cells activated (p&lt;0.01, r= -0.191), and M2 type macrophages (p&lt;0.01, r= -0.246). Conversely, a positive correlation between neutrophils and three cells was demonstrated, including Dendritic cells active (p&lt;0.01, r= 0.236), monocytes (p&lt; 0.01, r= 0.251), and Mast cells activated (p&lt;0.01, r= 0.289).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Immune cells infiltrating analysis. <bold>(A)</bold> The enrichment fraction of 22 types of immune infiltrating cells in the COPD and normal samples. <bold>(B)</bold> Box plot of 22 types of immune infiltrating cells in the COPD and normal samples. Normal samples were denoted by red, whereas COPD samples were denoted by green. <bold>(C)</bold> The heat map of the correlation among immune infiltrating cells. The color shade of the squares indicated the strength of the connection; purple indicated a positive correlation, while green indicated a negative correlation. The darker the color, the stronger the correlation; *P &lt; 0.05, **P &lt; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1410158-g005.tif"/>
</fig>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Weighted gene co-expression network analysis in GSE57148</title>
<p>As shown in <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6A</bold>
</xref>, the clustering tree for samples screened out three abnormal samples, and 186 samples (96 COPD and 90 normal samples) remained for further analysis. Sequentially, based on the scale-free network, the best soft-threshold power of 14 was chosen. (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B</bold>
</xref>). These genes were clustered into 12 modules based on their similar co-expression characteristics (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6C</bold>
</xref>). The correlation analysis of modules and traits (neutrophils and COPD) illustrated that the orangered4 module and lightssteelblue1 module were significantly associated with neutrophils (p&lt;0.001, r= 0.5; p&lt;0.001, r= -0.48) and COPD (p&lt;0.001, r= 0.31; p&lt;0.001, r= -0.46) (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6D</bold>
</xref>). Therefore, the genes in the orangered4 module and lightssteelblue1 module were selected as essential genes relevant to neutrophils for further analysis.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Weighted gene co-expression network analysis in GSE57148 dataset. <bold>(A)</bold> Sample clustering of GSE57148 to detect outliers. Three outliers were excluded, and all remaining clusters were selected for further analysis. <bold>(B)</bold> The optimal soft-threshold power. The threshold was 14. <bold>(C)</bold> Clustering dendrograms of genes based on a dissimilarity measure (1-TOM). Different modules were produced and shown in different colors by aggregating genes with strong correlations into the same module. <bold>(D)</bold> Correlations between module eigengenes and sample traits evaluated module-trait associations. The lightssteelblue1 module showed a significant negative correlation with neutrophils (COR = -0.48, P &lt; 0.001) and a significant negative correlation with COPD (COR = -0.46, P &lt; 0.001). The orangered4 module was significantly positively correlated with neutrophils (COR = 0.5, P &lt; 0.001) and positively correlated with COPD (COR = 0.31, P &lt; 0.001). Genes in the lightssteelblue1 and orangered4 modules were labeled as WGCNA-hub genes.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1410158-g006.tif"/>
</fig>
</sec>
<sec id="s3_6">
<label>3.6</label>
<title>Identification of DEGs</title>
<p>827 DEGs were identified between COPD and normal samples in GSE57148, including 390 upregulated and 437 downregulated genes (<xref ref-type="supplementary-material" rid="SF3">
<bold>Supplementary Figure&#xa0;3</bold>
</xref>). Venn diagrams were performed to obtain the DEG profiles intersection of scRNA-seq DEGs, RNA-seq, and WGCNA model genes, and 33 upregulated and 18 downregulated feature genes in total were remarkably expressed differentially in all 3 groups (<xref ref-type="fig" rid="f7">
<bold>Figures&#xa0;7A, D</bold>
</xref>, <xref ref-type="supplementary-material" rid="ST1">
<bold>Supplementary Table&#xa0;1</bold>
</xref>). KEGG pathway analysis revealed that the upregulated DEGs were mainly enriched in the IL-17 signaling pathway, NF-kappa B signaling pathway, and TNF signaling pathway. Meanwhile, the downregulated DEGs were primarily enriched in oxidative and collecting duct acid secretion (<xref ref-type="fig" rid="f7">
<bold>Figures&#xa0;7B, E</bold>
</xref>). The GO analysis showed that the upregulated DEGs were enriched in smooth muscle proliferation, secretory, and cytokine activity (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7C</bold>
</xref>). The downregulated DEGs were enriched in response to the metal ion, late endosome, and proton transmembrane transporter activity. (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7F</bold>
</xref>).</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Identification of DEGs and enrichment analysis of DEGs. <bold>(A, D)</bold> The intersection of single cell DEGs, WGCNA, and bulk RNA sequencing DEGs in Venn diagram. <bold>(B, C)</bold> GO and KEGG results of upregulated DEGs. The x-axis indicated the enrichment score associated with the terms, while the y-axis indicated the pathway terms. <bold>(E, F)</bold> GO and KEGG analyses of downregulated DEGs.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1410158-g007.tif"/>
</fig>
</sec>
<sec id="s3_7">
<label>3.7</label>
<title>MR analysis between feature DEGs and COPD</title>
<p>The MR analysis was used to explore the relationship between feature DEGs and COPD to verify whether the relationship was causal or correlative. Among these 51 feature DEGs, 9 genes were eliminated without suitable SNPs, and 2 genes had SNPs with P-value &lt; 5 &#xd7; 10<sup>&#x2013;6</sup>. <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref> and <xref ref-type="supplementary-material" rid="ST2">
<bold>Supplementary Table&#xa0;2</bold>
</xref> displayed the causal effect of each feature DEG on COPD. IVW analysis reveals that NAMPT (OR=1.0102, p=0.0064), PTGS2(OR=1.0139, p=0.0161), SLC2A3(OR=1.0052, p=0.0014) and TRIB1(OR=1.0172, p=0.0405) levels were associated with an increased risk of COPD, while CDKN1A (OR=0.9962, p=0.0169), and CSRNP1(OR=0.9933, p=0.0384) were related to a decreased risk of COPD. Information on SNPs and other MR estimates for 6 genes was shown in <xref ref-type="supplementary-material" rid="ST3">
<bold>Supplementary Table&#xa0;3</bold>
</xref>. The Cochran&#x2019;s Q test revealed no heterogeneity in these gene results. MR-Egger regression analysis indicated no horizontal pleiotropy in the results of these genes (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>MR analysis between feature DEGs and COPD.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Gene</th>
<th valign="middle" align="left">Nsnp</th>
<th valign="middle" align="left">Method</th>
<th valign="middle" align="left">P.value</th>
<th valign="middle" align="left">OR (95% CI)</th>
<th valign="middle" align="left">Heterogeneity_P.val</th>
<th valign="middle" align="left">Pleiotropy_P.val</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">CDKN1A</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Inverse variance weighted</td>
<td valign="middle" align="left">0.0169</td>
<td valign="middle" align="left">0.9962(0.9931 to 0.9993)</td>
<td valign="middle" align="left">0.6403</td>
<td valign="middle" align="left">0.9498</td>
</tr>
<tr>
<td valign="middle" align="left">CSRNP1</td>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">Inverse variance weighted</td>
<td valign="middle" align="left">0.0384</td>
<td valign="middle" align="left">0.9933(0.987 to 0.9996)</td>
<td valign="middle" align="left">0.7111</td>
<td valign="middle" align="left">0.9379</td>
</tr>
<tr>
<td valign="middle" align="left">NAMPT</td>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">Inverse variance weighted</td>
<td valign="middle" align="left">0.0064</td>
<td valign="middle" align="left">1.0102(1.0028 to 1.0175)</td>
<td valign="middle" align="left">0.8456</td>
<td valign="middle" align="left">0.4242</td>
</tr>
<tr>
<td valign="middle" align="left">PTGS2</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">Wald ratio</td>
<td valign="middle" align="left">0.0161</td>
<td valign="middle" align="left">1.0139(1.0026 to 1.0254)</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">SLC2A3</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Inverse variance weighted</td>
<td valign="middle" align="left">0.0014</td>
<td valign="middle" align="left">1.0052(1.002 to 1.0083)</td>
<td valign="middle" align="left">0.8848</td>
<td valign="middle" align="left">0.5695</td>
</tr>
<tr>
<td valign="middle" align="left">TRIB1</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">Wald ratio</td>
<td valign="middle" align="left">0.0405</td>
<td valign="middle" align="left">1.0172(1.0007 to 1.0338)</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>P.value&lt;0.05 was considered statistically significant</p>
</fn>
<fn>
<p>OR, odds ratio; CI, confidence interval.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_8">
<label>3.8</label>
<title>PPI network analysis and identification of hub genes</title>
<p>The protein&#x2013;protein interaction (PPI) network of 51 feature DEGs was constructed based on the STRING online database (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8A</bold>
</xref>). The interaction networks were visualized in Cytoscape and contained 25 nodes and 47 edges. Furthermore, we implemented the cytoHubba plugin to search for the most significant hub genes by the maximal clique centrality algorithm (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8B</bold>
</xref>). The top 10 hub genes were identified, including IL1B, CXCL2, PTGS2, MCL1, SOD2, EGR1, CDKN1A, CXCL3, NAMPT, TNFAIP3, and ZFP36, and both NAMPT and MCL1 ranked 10th. The 11 hub genes were all upregulated genes. Correlation analysis revealed that these hub genes had a correlation with various immune cells, and all of them were significantly positively correlated with neutrophils (all P&lt;0.05) (<xref ref-type="fig" rid="f8">
<bold>Figures&#xa0;8C&#x2013;M</bold>
</xref>).</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>The PPI networks and hub genes were analyzed using the STRING database and Cytoscape software. <bold>(A)</bold> PPI network display. <bold>(B)</bold> Top 10 hub genes explored by CytoHubba. <bold>(C&#x2013;M)</bold> The correlation of 11 hub genes (IL1B, CXCL2, MCL1, SOD2, EGR1, PTGS2, CDKN1A, ZFP36, NAMPT, CXCL3, TNFAIP3) with the immune cells. The dot size represented the degree of correlation between the gene and the immune cell. The dot color indicated the P-value; the greener the color, the smaller the P-value.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1410158-g008.tif"/>
</fig>
</sec>
<sec id="s3_9">
<label>3.9</label>
<title>Validations of the hub genes</title>
<p>27 COPD patients and 27 healthy individuals provided peripheral blood samples. Since neutrophils make up about 70% of all leukocytes in peripheral blood, peripheral blood leukocytes were isolated from blood samples. The qRT-PCR in leukocytes was performed to verify hub genes. In <xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>, the clinical characteristics of two group subjects were compared. Compared with normal subjects, the mRNA levels of IL1B, CXCL2, PTGS2, MCL1, SOD2, EGR1, NAMPT, CXCL3, and ZFP36 were markedly higher in COPD patients (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9</bold>
</xref>). Moreover, correlation analysis revealed that IL1B, CXCL2, SOD2, NAMPT, and CXCL3 were inversely correlated with lung function in COPD patients (r = -0.4374, p&lt;0.05; r = -0.5292, p&lt;0.01; r = -0.4537, p&lt;0.05; r = -0.5617, p&lt;0.01; r = -0.5709, p&lt;0.01; respectively) (<xref ref-type="fig" rid="f10">
<bold>Figure&#xa0;10</bold>
</xref>).</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Overall subjects characteristics.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="center"/>
<th valign="top" align="center">Normal</th>
<th valign="top" align="center">COPD</th>
<th valign="top" align="center">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="center">Subjects</td>
<td valign="top" align="center">27</td>
<td valign="top" align="center">27</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="center">Age, y</td>
<td valign="top" align="center">61.70 (&#xb1; 5.876)</td>
<td valign="top" align="center">64.26 (&#xb1; 8.596)</td>
<td valign="top" align="center">0.2079</td>
</tr>
<tr>
<td valign="top" align="center">Male, %</td>
<td valign="top" align="center">27 (100%)</td>
<td valign="top" align="center">27 (100%)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="center">BMI</td>
<td valign="top" align="center">23.23 (&#xb1; 3.916)</td>
<td valign="top" align="center">21.74 (&#xb1; 3.698)</td>
<td valign="top" align="center">0.0952</td>
</tr>
<tr>
<td valign="top" align="center">FEV<sub>1</sub>/FVC</td>
<td valign="top" align="center"/>
<td valign="top" align="center">41.13 (&#xb1; 11.13)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="center">FEV<sub>1</sub>% pred</td>
<td valign="top" align="center"/>
<td valign="top" align="center">46.18 (&#xb1; 17.38)</td>
<td valign="top" align="center"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Data are shown as percentages and means &#xb1; SD.</p>
</fn>
<fn>
<p>BMI, Body mass index; FEV<sub>1</sub>, Forced expiratory volume in the first second.</p>
</fn>
<fn>
<p>FVC, Forced vital capacity.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f9" position="float">
<label>Figure&#xa0;9</label>
<caption>
<p>Experimental verification of the hub genes. The relative mRNA expressions of 11 genes in the COPD subjects and normal subjects were shown, including <bold>(A)</bold> IL1B, <bold>(B)</bold> CXCL2, <bold>(C)</bold> MCL1 <bold>(D)</bold> SOD2, <bold>(E)</bold> EGR1, <bold>(F)</bold> PTGS2, <bold>(G)</bold> CDKN1A, <bold>(H)</bold> ZFP36 <bold>(I)</bold> NAMPT, <bold>(J)</bold> CXCL3, <bold>(K)</bold> TNFAIP3. Results were expressed as mean &#xb1; SD; n=27 for normal and n=27 for COPD; **P &lt; 0.01, ***P &lt; 0.001 ns, no significance.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1410158-g009.tif"/>
</fig>
<fig id="f10" position="float">
<label>Figure&#xa0;10</label>
<caption>
<p>The correlation analysis between hub genes and lung function in COPD patients. The lung function was negatively associated with <bold>(A)</bold> IL1B expression and <bold>(B)</bold> CXCL2 expression, <bold>(C)</bold> SOD2 expression and <bold>(D)</bold> NAMPT expression, <bold>(E)</bold> CXCL3 expression, whereas no significant associations with the expressions of <bold>(F)</bold> PTGS2, <bold>(G)</bold> EGR1, <bold>(H)</bold> MCL1 and <bold>(I)</bold> ZFP36.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1410158-g010.tif"/>
</fig>
</sec>
<sec id="s3_10">
<label>3.10</label>
<title>The regulatory network construction of NAMPT and PTGS2</title>
<p>The intersection of 6 genes identified by Mendelian randomization and 9 genes elevated in peripheral blood leukocytes of COPD patients identified 2 more crucial genes, NAMPT and PTGS2 (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11A</bold>
</xref>). Furthermore, NAMPT was negatively correlated with lung function in COPD patients. Using the JASPAR database, a network of transcription factors (TFs) for two genes was constructed. TF network showed that 10 TFs were obtained, of which 2 were GATA3 and FOXL1 with degree &#x2265; 2. (<xref ref-type="fig" rid="f11">
<bold>Figure&#xa0;11B</bold>
</xref>).</p>
<fig id="f11" position="float">
<label>Figure&#xa0;11</label>
<caption>
<p>The regulatory network construction of NAMPT and PTGS2. <bold>(A)</bold> The intersection of MR-genes and validation-genes. Two hub genes (NAMPT and PTGS2) were identified. <bold>(B)</bold> Interaction network of TFs and genes for the two hub genes.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1410158-g011.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>COPD remains a significant global health challenge. Despite the best current therapies, patients with COPD have an alarmingly high mortality rate and often have limited therapeutic options. In 2019, the number of deaths and DALYs due to COPD globally was 3.28 million and 74.43 million, respectively (<xref ref-type="bibr" rid="B4">4</xref>). Therefore, it is critical to identify key molecular targets of cellular mechanisms in COPD. As demonstrated by numerous RCT trials (e.g., pivotal clinical trials of roflumilast and dupilumab, etc.), identifying these targets can greatly elucidate therapeutic regimens for individual patients, thereby facilitating the development of precision medicine (<xref ref-type="bibr" rid="B24">24</xref>). Neutrophil inflammation plays a central role in the pathophysiology of COPD and persists in the entire disease process, but targets for its action remain relatively scarce, making the identification of new biomarkers of neutrophilic inflammation critical to developing effective therapeutic options for COPD.</p>
<p>Neutrophils and their products are considered to be significant contributors to the inflammatory changes in the airways of COPD patients (<xref ref-type="bibr" rid="B25">25</xref>). During the development of COPD, neutrophils become overstimulated, and their activation and inhibition pathways are altered at the molecular level. This leads to increased infiltration, prolonged lifespan, heightened activation, and increased necrosis. These changes result in elevated levels of neutrophil products in the lungs, which can cause lung injury (<xref ref-type="bibr" rid="B26">26</xref>). Furthermore, the quantity and product of neutrophils in the blood and lung tissue correlate with the severity of the disease, as reflected in lung function (e.g., degree of airway obstruction and decline in FEV1) (<xref ref-type="bibr" rid="B26">26</xref>).</p>
<p>In this study, the scRNA-seq analysis of lung tissues from COPD patients and normal controls revealed that the genes in the inflammatory response pathway were significantly upregulated and enriched in neutrophils in COPD. In trajectory and enrichment analysis, COPD neutrophils differentiated later than from normal controls, implying a series of changes in the neutrophil state during the development of COPD. The latest differentiated neutrophils were mainly associated with the upregulation of inflammatory and immune responses, suggesting the reciprocal relations among neutrophils, inflammation, and COPD. It had been found that in the development of COPD, neutrophils became over-infiltrated, which led to the accumulation of large amounts of inflammatory modulators, including proteases associated with tissue damage and chemoattractants that recruit additional inflammatory cells (<xref ref-type="bibr" rid="B27">27</xref>). At the same time, neutrophils in COPD responded differently to many of the chemical signals regulating inflammation and immune responses compared to healthy individuals (<xref ref-type="bibr" rid="B26">26</xref>). To identify the underlying hub genes in the neutrophilic inflammation of COPD, immune infiltration analysis, WGCNA, and differential expression analysis were performed, and 51 neutrophil-related DEGs were selected. Next, 6 genes causally associated with COPD were identified by Mendelian randomization analysis, of which 4 genes were risk factors for COPD and 2 genes were protective factors. Meanwhile, 11 hub genes were identified by PPI analysis, 9 of which were markedly upregulated in COPD patients. Moreover, 5 genes were inversely correlated with lung function in patients with COPD. Finally, establishing a regulatory network of transcription factors related to NAMPT and PTGS2 could help explore important mechanisms of neutrophilic inflammation in COPD.</p>
<p>MCL-1 and EGR1 can further exacerbate airway inflammation in COPD. MCL-1 is an anti-apoptotic protein of the BCL-2 family (<xref ref-type="bibr" rid="B28">28</xref>).It is believed to prevent neutrophil apoptosis by binding to pro-apoptotic BCL-2 proteins, resulting in prolonged inflammation in the lung and airway (<xref ref-type="bibr" rid="B29">29</xref>).EGR-1 is an instant early responsive gene encoding a zinc finger transcription factor upregulated in mature neutrophils (<xref ref-type="bibr" rid="B30">30</xref>). It has been found to be consistently upregulated in advanced emphysema, exacerbating cigarette smoke-induced lung inflammation (<xref ref-type="bibr" rid="B31">31</xref>).IL1B and CXCL2 may also have an association with lung function in COPD. IL-1B, a member of the interleukin-1 family involved in neutrophil recruitment, may serve as a biomarker of persistent neutrophilic airway inflammation and potentially persistent exacerbations of COPD (<xref ref-type="bibr" rid="B32">32</xref>). It also has a significant negative correlation with lung function, such as predicted FEV1 percent and FEV1/FVC ratio (<xref ref-type="bibr" rid="B33">33</xref>). CXCL2 is a member of the chemokine CXC family, which can bind to CXCR2 on the surface of neutrophils to promote neutrophil migration (<xref ref-type="bibr" rid="B34">34</xref>). Up-regulation of CXCL2 expression promotes lung inflammation and increases airflow obstruction in COPD (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>). SOD2, also known as manganese superoxide dismutase, is a mitochondrial antioxidant enzyme that plays a bidirectional role in COPD (<xref ref-type="bibr" rid="B37">37</xref>). One study found that sputum SOD activity is a marker of COPD exacerbation, while another study concluded that SOD2 ameliorates mitochondrial oxidative stress and cellular damage in COPD (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>).ZFP36 encodes triple trehalose (TTP), which transcriptionally inhibits many pro-inflammatory factors associated with COPD and may regulate neutrophil homeostasis (<xref ref-type="bibr" rid="B40">40</xref>).The up-regulation of ZFP36 expression was associated with a reduction in lung inflammation, airway remodeling, and emphysema-like alveolar enlargement, which may suggest a protective role for ZFP36 in the development of COPD (<xref ref-type="bibr" rid="B41">41</xref>). Similar to CXCL2, CXCL3 is also an inflammatory factor of the CXC chemokine family and can bind to CXCR2 on the surface of neutrophils (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>). A previous scRNA-seq study on lung tissue in septic lung injury revealed that the Neutrophil-CXCL3-High subpopulation was closely related to the hyperinflammatory response (<xref ref-type="bibr" rid="B44">44</xref>). So far, the function of CXCL3 in COPD is poorly understood. This study may offer a new insight into the role of CXCL3 in the neutrophilic inflammation of COPD.</p>
<p>Among the 9 hub genes, NAMPT and PTGS2 were further confirmed by MR analysis as risk factors for COPD. NAMPT is a specific enzyme with cytokine-like characteristics that have been shown to play a substantial role in inflammation, cellular metabolism, and immune regulation (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>). Intracellularly, it catalyzes the conversion of nicotinamide into NAD. However, extracellularly, it acts as a cytokine to convey various signals, including promoting myeloid cell differentiation/polarization, activating inflammatory vesicles, and secretion of pro- or anti-inflammatory cytokines (<xref ref-type="bibr" rid="B47">47</xref>). During G-CSF-stimulated granulopoiesis, NAMPT was essential for regulating neutrophil development and functionality (<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>). In tumors, breast tumor derived NAMP activated SIRT1 in neutrophils, which polarized neutrophils into tumor-associated aged neutrophils, thus promoting tumor metastasis (<xref ref-type="bibr" rid="B50">50</xref>). In addition, NAMPT functioned as a novel inflammatory cytokine in LPS-stimulated sepsis and exerted inhibitory effects on the apoptosis of neutrophils by decreasing the activity of caspase-3 and caspase-8 (<xref ref-type="bibr" rid="B51">51</xref>). NAMPT has also been reported to regulate CXCL2 to recruit neutrophils to exacerbate neutrophil-induced tissue injury in myocardial infarction (<xref ref-type="bibr" rid="B52">52</xref>). Meanwhile, intracellular NAMPT exerts its function in LPS-induced neutrophil extracellular traps-related diseases (<xref ref-type="bibr" rid="B53">53</xref>). In this study, NAMPT was significantly upregulated in COPD neutrophils and may be involved in neutrophil inflammation in the development of COPD through the related mechanisms, which may be helpful in the diagnosis and treatment of COPD.</p>
<p>PTGS2, also known as cycloxygenase-2 (COX-2), is a key enzyme in promoting the rate-limiting step of prostaglandin synthesis (<xref ref-type="bibr" rid="B54">54</xref>). PTGS2 and its derivative prostaglandin E2 (PGE2) have been found to play an essential pro-inflammatory role in various diseases (<xref ref-type="bibr" rid="B55">55</xref>). In COPD, PGE2, the derivative of PTGS2, promotes the aggregation of neutrophils in the lungs, which can further increase the ability of neutrophils to adhere to human airway epithelial cells, thus exerting a pro-inflammatory effect (<xref ref-type="bibr" rid="B56">56</xref>). Meanwhile, activated neutrophils in COPD patients produce large amounts of reactive oxygen species (ROS), leading to the oxidation of arachidonic acid, which can be converted to prostaglandins through the action of COX2 and participate in the inflammatory response in COPD (<xref ref-type="bibr" rid="B57">57</xref>). In obese women, vascular inflammation is strongly associated with neutrophil infiltration, and COX-2 staining is highly correlated with the neutrophil marker CD66b staining, suggesting that COX2 may be associated with neutrophil inflammation (<xref ref-type="bibr" rid="B58">58</xref>). During acute inflammation, when neutrophils are exposed to bacterial endotoxins, cytokines, and hormones, they evoke activation of mitogen-activated protein kinase (MAPK) and nuclear factor-&#x3ba;B (NF-&#x3ba;B), which in turn promotes the expression of COX-2 and production of PGE2 (<xref ref-type="bibr" rid="B59">59</xref>), which also has a vital role in the regulation of inflammatory nociceptive hypersensitivity (<xref ref-type="bibr" rid="B60">60</xref>). Meanwhile, it has been found that bioactive implants can recruit neutrophils and trigger neutrophil extracellular traps during osseointegration, which are effective in promoting PGE2 production (<xref ref-type="bibr" rid="B61">61</xref>). All these facts suggest that PTGS2 is closely related to neutrophil inflammation, and the mechanism of PTGS2-induced neutrophil inflammation in COPD needs further exploration.</p>
<p>Although this study reveals significant findings, there are limitations. First, the number of cases we studied was relatively insufficient. This needs to be validated in a larger clinical sample. Secondly, we only studied the mRNA expression levels of the hub genes in peripheral blood leukocytes, and further validation is needed <italic>in vivo</italic> and <italic>in vitro</italic>, including the protein levels of the hub genes and their mechanisms in neutrophils in COPD development. Nevertheless, our study may provide new marker genes for neutrophilic inflammation in COPD. It may also provide a theoretical basis for further research.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusion</title>
<p>In this research, 9 hub genes associated with neutrophil inflammation were identified by analyzing scRNA-seq and RNA-seq data in COPD and control lung tissue samples, of which 5 genes were negatively correlated with lung function in COPD patients. NAMPT and PTGS2 were further confirmed as risk factors for COPD by MR analysis, providing a novel way to detect neutrophilic inflammation and lung function in COPD. Therefore, the present study offers an idea for further research into the mechanisms of neutrophilic inflammation in COPD, which could lead to the development of new therapeutic targets.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding author/s.</p>
</sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Tongji Medical Ethics Committee, Tongji Medical College, Huazhong University of Science and Technology, China. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>YHu: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. YN: Writing &#x2013; review &amp; editing, Formal analysis, Software. XW: Writing &#x2013; review &amp; editing, Data curation, Resources. XCL: Writing &#x2013; review &amp; editing. YHe: Writing &#x2013; review &amp; editing. XSL: Writing &#x2013; review &amp; editing, Funding acquisition, Conceptualization, Project administration.</p>
</sec>
</body>
<back>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by the National Natural Science Foundation of China (Grant No. 81973987).</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We appreciate the contributors to the public databases and all patients enrolled in our research.</p>
</ack>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s12" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2024.1410158/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2024.1410158/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image_1.tif" id="SF1" mimetype="image/tiff">
<label>Supplementary Figure&#xa0;1</label>
<caption>
<p>
<bold>(A)</bold> KEGG results of upregulated DEGs in neutrophils. The size of the bubble represented the number of enriched genes. The enriched pathways were connected to their corresponding genes with the same colored lines. Each gene&#x2019;s fold change was colored according to the legend. <bold>(B)</bold> GO results of upregulated DEGs in neutrophils. The x-axis indicated the enrichment score associated with the terms, while the y-axis indicated the pathway terms. <bold>(C)</bold> KEGG results of downregulated DEGs in neutrophils. <bold>(D)</bold> GO results of downregulated DEGs in neutrophils.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Image_2.tif" id="SF2" mimetype="image/tiff">
<label>Supplementary Figure&#xa0;2</label>
<caption>
<p>Enrichment analysis of DEGs of three stages of neutrophil differentiation in scRNA-seq GSE173896. <bold>(A)</bold> GSEA of DEGs on GO in state.1. <bold>(B)</bold> GSEA of DEGs on GO in state.2. <bold>(C)</bold> GSEA of DEGs on GO in state.3.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Image_3.tif" id="SF3" mimetype="image/tiff">
<label>Supplementary Figure&#xa0;3</label>
<caption>
<p>Volcano plot showing DEGs in GSE57148. Blue represented low-expressed genes in COPD lung tissues, red represented high-expressed genes in COPD lung tissues, and black represented genes with no significant difference.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Table_1.xlsx" id="ST1" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="Table_2.xlsx" id="ST2" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
<supplementary-material xlink:href="Table_3.xlsx" id="ST3" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agust&#xed;</surname> <given-names>A</given-names>
</name>
<name>
<surname>Barnes</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Update in chronic obstructive pulmonary disease 2011</article-title>. <source>Am J Respir Crit Care Med</source>. (<year>2012</year>) <volume>185</volume>:<page-range>1171&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1164/rccm.201203-0505UP</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cosio</surname> <given-names>MG</given-names>
</name>
<name>
<surname>Saetta</surname> <given-names>M</given-names>
</name>
<name>
<surname>Agusti</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Immunologic aspects of chronic obstructive pulmonary disease</article-title>. <source>N Engl J Med</source>. (<year>2009</year>) <volume>360</volume>:<page-range>2445&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMra0804752</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Shibuya</surname> <given-names>K</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mathers</surname> <given-names>CD</given-names>
</name>
<name>
<surname>Hansell</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Held</surname> <given-names>LS</given-names>
</name>
<etal/>
</person-group>. <article-title>Chronic obstructive pulmonary disease: current burden and future projections</article-title>. <source>Eur Respir J</source>. (<year>2006</year>) <volume>27</volume>:<fpage>397</fpage>&#x2013;<lpage>412</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1183/09031936.06.00025805</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Safiri</surname> <given-names>S</given-names>
</name>
<name>
<surname>Carson-Chahhoud</surname> <given-names>K</given-names>
</name>
<name>
<surname>Noori</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nejadghaderi</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Sullman</surname> <given-names>MJM</given-names>
</name>
<name>
<surname>Ahmadian Heris</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990&#x2013;2019: results from the Global Burden of Disease Study 2019</article-title>. <source>BMJ</source>. (<year>2022</year>) <volume>378</volume>:<elocation-id>e069679</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmj-2021&#x2013;069679</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Airway inflammation biomarker for precise management of neutrophil-predominant COPD</article-title>. <source>Methods Mol Biol</source>. (<year>2020</year>) <volume>2204</volume>:<page-range>181&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978&#x2013;1-0716&#x2013;0904-0_16</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname> <given-names>A</given-names>
</name>
<name>
<surname>Walton</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Sapey</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Neutrophilic inflammation in the pathogenesis of chronic obstructive pulmonary disease</article-title>. <source>COPD</source>. (<year>2018</year>) <volume>15</volume>:<fpage>392</fpage>&#x2013;<lpage>404</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/15412555.2018.1476475</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>P</given-names>
</name>
<name>
<surname>Li</surname> <given-names>R</given-names>
</name>
<name>
<surname>Piao</surname> <given-names>TH</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>XL</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>HY</given-names>
</name>
</person-group>. <article-title>Pathological mechanism and targeted drugs of COPD</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source>. (<year>2022</year>) <volume>17</volume>:<page-range>1565&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/COPD.S366126</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartoli</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Costa</surname> <given-names>F</given-names>
</name>
<name>
<surname>Malagrin&#xf2;</surname> <given-names>L</given-names>
</name>
<name>
<surname>Nieri</surname> <given-names>D</given-names>
</name>
<name>
<surname>Antonelli</surname> <given-names>S</given-names>
</name>
<name>
<surname>Decusatis</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Sputum inflammatory cells in COPD patients classified according to GOLD 2011 guidelines</article-title>. <source>Eur Respir J</source>. (<year>2016</year>) <volume>47</volume>:<page-range>978&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1183/13993003.00784&#x2013;2015</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kapellos</surname> <given-names>TS</given-names>
</name>
<name>
<surname>Ba&#xdf;ler</surname> <given-names>K</given-names>
</name>
<name>
<surname>Fujii</surname> <given-names>W</given-names>
</name>
<name>
<surname>Nalkurthi</surname> <given-names>C</given-names>
</name>
<name>
<surname>Schaar</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Bonaguro</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Systemic alterations in neutrophils and their precursors in early-stage chronic obstructive pulmonary disease</article-title>. <source>Cell Rep</source>. (<year>2023</year>) <volume>42</volume>:<elocation-id>112525</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2023.112525</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekula</surname> <given-names>P</given-names>
</name>
<name>
<surname>Del Greco M</surname> <given-names>F</given-names>
</name>
<name>
<surname>Pattaro</surname> <given-names>C</given-names>
</name>
<name>
<surname>K&#xf6;ttgen</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Mendelian randomization as an approach to assess causality using observational data</article-title>. <source>J Am Soc Nephrol</source>. (<year>2016</year>) <volume>27</volume>:<page-range>3253&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1681/ASN.2016010098</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hao</surname> <given-names>S</given-names>
</name>
<name>
<surname>Andersen-Nissen</surname> <given-names>E</given-names>
</name>
<name>
<surname>Mauck</surname> <given-names>WM</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Butler</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Integrated analysis of multimodal single-cell data</article-title>. <source>Cell</source>. (<year>2021</year>) <volume>184</volume>:<page-range>3573&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2021.04.048</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becht</surname> <given-names>E</given-names>
</name>
<name>
<surname>McInnes</surname> <given-names>L</given-names>
</name>
<name>
<surname>Healy</surname> <given-names>J</given-names>
</name>
<name>
<surname>Dutertre</surname> <given-names>C-A</given-names>
</name>
<name>
<surname>Kwok</surname> <given-names>IWH</given-names>
</name>
<name>
<surname>Ng</surname> <given-names>LG</given-names>
</name>
<etal/>
</person-group>. <article-title>Dimensionality reduction for visualizing single-cell data using UMAP</article-title>. <source>Nat Biotechnol</source>. (<year>2018</year>) <volume>37</volume>:<page-range>38&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nbt.4314</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chawla</surname> <given-names>R</given-names>
</name>
<name>
<surname>Pliner</surname> <given-names>HA</given-names>
</name>
<etal/>
</person-group>. <article-title>Reversed graph embedding resolves complex single-cell trajectories</article-title>. <source>Nat Methods</source>. (<year>2017</year>) <volume>14</volume>:<page-range>979&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nmeth.4402</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newman</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Green</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Gentles</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Robust enumeration of cell subsets from tissue expression profiles</article-title>. <source>Nat Methods</source>. (<year>2015</year>) <volume>12</volume>:<page-range>453&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nmeth.3337</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Horvath</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>A general framework for weighted gene co-expression network analysis</article-title>. <source>Stat Appl Genet Mol Biol</source>. (<year>2005</year>) <volume>4</volume>:<fpage>Article17</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2202/1544-6115.1128</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>G</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L-G</given-names>
</name>
<name>
<surname>Han</surname> <given-names>Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>Q-Y</given-names>
</name>
</person-group>. <article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title>. <source>OMICS</source>. (<year>2012</year>) <volume>16</volume>:<page-range>284&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>V&#xf5;sa</surname> <given-names>U</given-names>
</name>
<name>
<surname>Claringbould</surname> <given-names>A</given-names>
</name>
<name>
<surname>Westra</surname> <given-names>H-J</given-names>
</name>
<name>
<surname>Bonder</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Deelen</surname> <given-names>P</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression</article-title>. <source>Nat Genet</source>. (<year>2021</year>) <volume>53</volume>:<page-range>1300&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41588&#x2013;021-00913-z</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elsworth</surname> <given-names>B</given-names>
</name>
<name>
<surname>Lyon</surname> <given-names>M</given-names>
</name>
<name>
<surname>Alexander</surname> <given-names>T</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Matthews</surname> <given-names>P</given-names>
</name>
<name>
<surname>Hallett</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>The MRC IEU OpenGWAS data infrastructure</article-title>. <source>bioRxiv</source>. (<year>2020</year>). doi:&#xa0;<pub-id pub-id-type="doi">10.1101/2020.08.10.244293</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higgins</surname> <given-names>JPT</given-names>
</name>
<name>
<surname>Thompson</surname> <given-names>SG</given-names>
</name>
<name>
<surname>Deeks</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Altman</surname> <given-names>DG</given-names>
</name>
</person-group>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source>. (<year>2003</year>) <volume>327</volume>:<page-range>557&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burgess</surname> <given-names>S</given-names>
</name>
<name>
<surname>Thompson</surname> <given-names>SG</given-names>
</name>
</person-group>. <article-title>Interpreting findings from Mendelian randomization using the MR-Egger method</article-title>. <source>Eur J Epidemiol</source>. (<year>2017</year>) <volume>32</volume>:<page-range>377&#x2013;89</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10654-017-0255-x</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname> <given-names>D</given-names>
</name>
<name>
<surname>Gable</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Nastou</surname> <given-names>KC</given-names>
</name>
<name>
<surname>Lyon</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kirsch</surname> <given-names>R</given-names>
</name>
<name>
<surname>Pyysalo</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets</article-title>. <source>Nucleic Acids Res</source>. (<year>2021</year>) <volume>49</volume>:<page-range>D605&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nar/gkaa1074</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fornes</surname> <given-names>O</given-names>
</name>
<name>
<surname>Castro-Mondragon</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>A</given-names>
</name>
<name>
<surname>van der Lee</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Richmond</surname> <given-names>PA</given-names>
</name>
<etal/>
</person-group>. <article-title>JASPAR 2020: update of the open-access database of transcription factor binding profiles</article-title>. <source>Nucleic Acids Res</source>. (<year>2020</year>) <volume>48</volume>:<page-range>D87&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nar/gkz1001</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>G</given-names>
</name>
<name>
<surname>Soufan</surname> <given-names>O</given-names>
</name>
<name>
<surname>Ewald</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hancock</surname> <given-names>REW</given-names>
</name>
<name>
<surname>Basu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis</article-title>. <source>Nucleic Acids Res</source>. (<year>2019</year>) <volume>47</volume>:<page-range>W234&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nar/gkz240</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolger</surname> <given-names>GB</given-names>
</name>
</person-group>. <article-title>Therapeutic targets and precision medicine in COPD: Inflammation, ion channels, both, or neither</article-title>? <source>Int J Mol Sci</source>. (<year>2023</year>) <volume>24</volume>:<fpage>17363</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms242417363</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uddin</surname> <given-names>M</given-names>
</name>
<name>
<surname>Watz</surname> <given-names>H</given-names>
</name>
<name>
<surname>Malmgren</surname> <given-names>A</given-names>
</name>
<name>
<surname>Pedersen</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>NETopathic inflammation in chronic obstructive pulmonary disease and severe asthma</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>47</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00047</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meijer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rijkers</surname> <given-names>GT</given-names>
</name>
<name>
<surname>van Overveld</surname> <given-names>FJ</given-names>
</name>
</person-group>. <article-title>Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease</article-title>. <source>Expert Rev Clin Immunol</source>. (<year>2013</year>) <volume>9</volume>:<page-range>1055&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1586/1744666X.2013.851347</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Inflammatory mechanisms in patients with chronic obstructive pulmonary disease</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2016</year>) <volume>138</volume>:<fpage>16</fpage>&#x2013;<lpage>27</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2016.05.011</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fletcher</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>MCL-1 inhibitors - where are we now (2019)</article-title>? <source>Expert Opin Ther Pat</source>. (<year>2019</year>) <volume>29</volume>:<page-range>909&#x2013;19</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/13543776.2019.1672661</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>He</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Delayed apoptosis by neutrophils from COPD patients is associated with altered Bak, Bcl-xl, and Mcl-1 mRNA expression</article-title>. <source>Diagn Pathol</source>. (<year>2012</year>) <volume>7</volume>:<elocation-id>65</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1746&#x2013;1596-7&#x2013;65</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cullen</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Brazil</surname> <given-names>JC</given-names>
</name>
<name>
<surname>O'Connor</surname> <given-names>CM</given-names>
</name>
</person-group>. <article-title>Mature human neutrophils constitutively express the transcription factor EGR-1</article-title>. <source>Mol Immunol</source>. (<year>2010</year>) <volume>47</volume>:<page-range>1701&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2010.03.003</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Role of early growth response 1 in inflammation-associated lung diseases</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. (<year>2023</year>) <volume>325</volume>:<page-range>L143&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/ajplung.00413.2022</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pauwels</surname> <given-names>NS</given-names>
</name>
<name>
<surname>Bracke</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Dupont</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Van Pottelberge</surname> <given-names>GR</given-names>
</name>
<name>
<surname>Provoost</surname> <given-names>S</given-names>
</name>
<name>
<surname>Vanden Berghe</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of IL-1&#x3b1; and the Nlrp3/caspase-1/IL-1&#x3b2; axis in cigarette smoke-induced pulmonary inflammation and COPD</article-title>. <source>Eur Respir J</source>. (<year>2011</year>) <volume>38</volume>:<page-range>1019&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1183/09031936.00158110</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>DB</given-names>
</name>
<name>
<surname>Kuang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Serum IL-1&#x3b2; and IL-17 levels in patients with COPD: associations with clinical parameters</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source>. (<year>2017</year>) <volume>12</volume>:<page-range>1247&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/COPD.S131877</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girbl</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lenn</surname> <given-names>T</given-names>
</name>
<name>
<surname>Perez</surname> <given-names>L</given-names>
</name>
<name>
<surname>Rolas</surname> <given-names>L</given-names>
</name>
<name>
<surname>Barkaway</surname> <given-names>A</given-names>
</name>
<name>
<surname>Thiriot</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Distinct compartmentalization of the chemokines CXCL1 and CXCL2 and the atypical receptor ACKR1 determine discrete stages of neutrophil diapedesis</article-title>. <source>Immunity</source>. (<year>2018</year>) <volume>49</volume>:<page-range>1062&#x2013;76</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2018.09.018</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiwari</surname> <given-names>N</given-names>
</name>
<name>
<surname>Marudamuthu</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Tsukasaki</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ikebe</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shetty</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>p53- and PAI-1-mediated induction of C-X-C chemokines and CXCR2: importance in pulmonary inflammation due to cigarette smoke exposure</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. (<year>2016</year>) <volume>310</volume>:<page-range>L496&#x2013;506</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/ajplung.00290.2015</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thatcher</surname> <given-names>TH</given-names>
</name>
<name>
<surname>McHugh</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Egan</surname> <given-names>RW</given-names>
</name>
<name>
<surname>Chapman</surname> <given-names>RW</given-names>
</name>
<name>
<surname>Hey</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Turner</surname> <given-names>CK</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of CXCR2 in cigarette smoke-induced lung inflammation</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. (<year>2005</year>) <volume>289</volume>:<page-range>L322&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/ajplung.00039.2005</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miao</surname> <given-names>L</given-names>
</name>
<name>
<surname>St Clair</surname> <given-names>DK</given-names>
</name>
</person-group>. <article-title>Regulation of superoxide dismutase genes: implications in disease</article-title>. <source>Free Radic Biol Med</source>. (<year>2009</year>) <volume>47</volume>:<page-range>344&#x2013;56</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2009.05.018</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Roth</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Sirtuin 3 inhibits airway epithelial mitochondrial oxidative stress in cigarette smoke-induced COPD</article-title>. <source>Oxid Med Cell Longev</source>. (<year>2020</year>) <volume>2020</volume>:<elocation-id>7582980</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2020/7582980</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stringer</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Freed</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Dunn</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Sayers</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gustafson</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Flores</surname> <given-names>SC</given-names>
</name>
</person-group>. <article-title>Particulate phase cigarette smoke increases MnSOD, NQO1, and CINC-1 in rat lungs</article-title>. <source>Free Radic Biol Med</source>. (<year>2004</year>) <volume>37</volume>:<page-range>1527&#x2013;33</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2004.08.008</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ebner</surname> <given-names>F</given-names>
</name>
<name>
<surname>Sedlyarov</surname> <given-names>V</given-names>
</name>
<name>
<surname>Tasciyan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ivin</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kratochvill</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gratz</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>The RNA-binding protein tristetraprolin schedules apoptosis of pathogen-engaged neutrophils during bacterial infection</article-title>. <source>J Clin Invest</source>. (<year>2017</year>) <volume>127</volume>:<page-range>2051&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI80631</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antus</surname> <given-names>B</given-names>
</name>
<name>
<surname>Paska</surname> <given-names>C</given-names>
</name>
<name>
<surname>Simon</surname> <given-names>B</given-names>
</name>
<name>
<surname>Barta</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Monitoring antioxidant enzyme activity during exacerbations of chronic obstructive pulmonary disease</article-title>. <source>COPD</source>. (<year>2018</year>) <volume>15</volume>:<fpage>496</fpage>&#x2013;<lpage>502</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/15412555.2018.1535581</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korbecki</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kojder</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kapczuk</surname> <given-names>P</given-names>
</name>
<name>
<surname>Kupnicka</surname> <given-names>P</given-names>
</name>
<name>
<surname>Gawro&#x144;ska-Szklarz</surname> <given-names>B</given-names>
</name>
<name>
<surname>Gutowska</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors-A review of literature</article-title>. <source>Int J Mol Sci</source>. (<year>2021</year>) <volume>22</volume>:<fpage>843</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms22020843</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajarathnam</surname> <given-names>K</given-names>
</name>
<name>
<surname>Schnoor</surname> <given-names>M</given-names>
</name>
<name>
<surname>Richardson</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Rajagopal</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>How do chemokines navigate neutrophils to the target site: Dissecting the structural mechanisms and signaling pathways</article-title>. <source>Cell Signal</source>. (<year>2019</year>) <volume>54</volume>:<fpage>69</fpage>&#x2013;<lpage>80</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cellsig.2018.11.004</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Single-cell sequencing reveals the regulatory role of maresin1 on neutrophils during septic lung injury</article-title>. <source>Cells</source>. (<year>2022</year>) <volume>11</volume>:<fpage>3733</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells11233733</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montecucco</surname> <given-names>F</given-names>
</name>
<name>
<surname>Cea</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cagnetta</surname> <given-names>A</given-names>
</name>
<name>
<surname>Damonte</surname> <given-names>P</given-names>
</name>
<name>
<surname>Nahimana</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ballestrero</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders</article-title>. <source>Curr Top Med Chem</source>. (<year>2013</year>) <volume>13</volume>:<page-range>2930&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/15680266113136660208</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garten</surname> <given-names>A</given-names>
</name>
<name>
<surname>Petzold</surname> <given-names>S</given-names>
</name>
<name>
<surname>Schuster</surname> <given-names>S</given-names>
</name>
<name>
<surname>K&#xf6;rner</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kratzsch</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kiess</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Nampt and its potential role in inflammation and type 2 diabetes</article-title>. <source>Handb Exp Pharmacol</source>. (<year>2011</year>) <volume>203</volume>:<page-range>147&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978&#x2013;3-642&#x2013;17214-4_7</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Audrito</surname> <given-names>V</given-names>
</name>
<name>
<surname>Messana</surname> <given-names>VG</given-names>
</name>
<name>
<surname>Deaglio</surname> <given-names>S</given-names>
</name>
<name>
<surname>NAMPT and</surname> <given-names>NAPRT</given-names>
</name>
</person-group>. <article-title>Two metabolic enzymes with key roles in inflammation</article-title>. <source>Front Oncol</source>. (<year>2020</year>) <volume>10</volume>:<elocation-id>358</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2020.00358</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skokowa</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Thakur</surname> <given-names>BK</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gupta</surname> <given-names>K</given-names>
</name>
<name>
<surname>Cario</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway</article-title>. <source>Nat Med</source>. (<year>2009</year>) <volume>15</volume>:<page-range>151&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm.1913</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siakaeva</surname> <given-names>E</given-names>
</name>
<name>
<surname>Pylaeva</surname> <given-names>E</given-names>
</name>
<name>
<surname>Spyra</surname> <given-names>I</given-names>
</name>
<name>
<surname>Bordbari</surname> <given-names>S</given-names>
</name>
<name>
<surname>H&#xf6;ing</surname> <given-names>B</given-names>
</name>
<name>
<surname>K&#xfc;rten</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Neutrophil maturation and survival is controlled by IFN-dependent regulation of NAMPT signaling</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>20</volume>:<fpage>5584</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms20225584</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Aged neutrophils form mitochondria-dependent vital NETs to promote breast cancer lung metastasis</article-title>. <source>J Immunother Cancer</source>. (<year>2021</year>) <volume>9</volume>:<fpage>e002875</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/jitc-2021&#x2013;002875</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Parodo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kapus</surname> <given-names>A</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>L</given-names>
</name>
<name>
<surname>Rotstein</surname> <given-names>OD</given-names>
</name>
<etal/>
</person-group>. <article-title>Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis</article-title>. <source>J Clin Invest</source>. (<year>2004</year>) <volume>113</volume>:<page-range>1318&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI200419930</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montecucco</surname> <given-names>F</given-names>
</name>
<name>
<surname>Bauer</surname> <given-names>I</given-names>
</name>
<name>
<surname>Braunersreuther</surname> <given-names>V</given-names>
</name>
<name>
<surname>Bruzzone</surname> <given-names>S</given-names>
</name>
<name>
<surname>Akhmedov</surname> <given-names>A</given-names>
</name>
<name>
<surname>L&#xfc;scher</surname> <given-names>TF</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction</article-title>. <source>Antioxid Redox Signal</source>. (<year>2013</year>) <volume>18</volume>:<page-range>630&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/ars.2011.4487</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Bi</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in LPS-induced neutrophil extracellular traps</article-title>. <source>Microbiol Immunol</source>. (<year>2021</year>) <volume>65</volume>:<page-range>257&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/1348&#x2013;0421.12885</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mart&#xed;n-V&#xe1;zquez</surname> <given-names>E</given-names>
</name>
<name>
<surname>Cobo-Vuilleumier</surname> <given-names>N</given-names>
</name>
<name>
<surname>L&#xf3;pez-Noriega</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lorenzo</surname> <given-names>PI</given-names>
</name>
<name>
<surname>Gauthier</surname> <given-names>BR</given-names>
</name>
</person-group>. <article-title>The PTGS2/COX2-PGE2 signaling cascade in inflammation: Pro or anti</article-title>? <source>A Case study type 1 Diabetes mellitus. Int J Biol Sci</source>. (<year>2023</year>) <volume>19</volume>:<page-range>4157&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7150/ijbs.86492</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrer</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Busquets-Cort&#xe9;s</surname> <given-names>C</given-names>
</name>
<name>
<surname>Cap&#xf3;</surname> <given-names>X</given-names>
</name>
<name>
<surname>Tejada</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tur</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Pons</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases</article-title>. <source>Curr Med Chem</source>. (<year>2019</year>) <volume>26</volume>:<page-range>3225&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/0929867325666180514112124</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Profita</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sala</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bonanno</surname> <given-names>A</given-names>
</name>
<name>
<surname>Riccobono</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ferraro</surname> <given-names>M</given-names>
</name>
<name>
<surname>La Grutta</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. (<year>2010</year>) <volume>298</volume>:<page-range>L261&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/ajplung.90593.2008</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sant'Ana</surname> <given-names>M</given-names>
</name>
<name>
<surname>Souza</surname> <given-names>HR</given-names>
</name>
<name>
<surname>Possebon</surname> <given-names>L</given-names>
</name>
<name>
<surname>Corn&#xe9;lio</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Riffo-Vasquez</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Girol</surname> <given-names>AP</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of piperlongumine during exposure to cigarette smoke reduces inflammation and lung injury</article-title>. <source>Pulm Pharmacol Ther</source>. (<year>2020</year>) <volume>61</volume>:<elocation-id>101896</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.pupt.2020.101896</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname> <given-names>TJ</given-names>
</name>
<name>
<surname>Leik</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Walsh</surname> <given-names>SW</given-names>
</name>
</person-group>. <article-title>Neutrophil infiltration and systemic vascular inflammation in obese women</article-title>. <source>Reprod Sci</source>. (<year>2010</year>) <volume>17</volume>:<page-range>116&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/1933719109348252</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pace</surname> <given-names>S</given-names>
</name>
<name>
<surname>Rossi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Krauth</surname> <given-names>V</given-names>
</name>
<name>
<surname>Dehm</surname> <given-names>F</given-names>
</name>
<name>
<surname>Troisi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Bilancia</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Sex differences in prostaglandin biosynthesis in neutrophils during acute inflammation</article-title>. <source>Sci Rep</source>. (<year>2017</year>) <volume>7</volume>:<fpage>3759</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598&#x2013;017-03696&#x2013;8</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carvalho</surname> <given-names>NS</given-names>
</name>
<name>
<surname>Lemes</surname> <given-names>JBP</given-names>
</name>
<name>
<surname>Pagliusi</surname> <given-names>M</given-names>
</name>
<name>
<surname>MaChado</surname> <given-names>ACDS</given-names>
</name>
<name>
<surname>Malange</surname> <given-names>KF</given-names>
</name>
<name>
<surname>Pral</surname> <given-names>LP</given-names>
</name>
<etal/>
</person-group>. <article-title>Neutrophil-Derived COX-2 has a Key Role during Inflammatory Hyperalgesia</article-title>. <source>Inflammation</source>. (<year>2022</year>) <volume>45</volume>:<page-range>2280&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10753&#x2013;022-01690&#x2013;5</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vitkov</surname> <given-names>L</given-names>
</name>
<name>
<surname>Hartl</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hannig</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Is osseointegration inflammation-triggered</article-title>? <source>Med Hypotheses</source>. (<year>2016</year>) <volume>93</volume>:<fpage>1</fpage>&#x2013;<lpage>4</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mehy.2016.05.004</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>